Quanyi Yin | Vice General Manager
Chongqing BDSyn Biotech Co., Ltd,

Dr. Quanyi Yin received his Ph.D. in Materials Chemistry from the University of Lyon, France. His research focuses on functional biomaterials and immune delivery systems, with a strong interdisciplinary background spanning chemical synthesis, nanotechnology-based formulations, and immunological evaluation. He has long been engaged in the technological development and industrial translation of novel vaccine adjuvants, leading and contributing to multiple adjuvant platform initiatives. Dr. Yin has accumulated extensive experience in the rational design of synthetic adjuvants, formulation engineering, and mechanism-of-action studies. His team has successfully achieved the full chemical synthesis of QS-21 saponin adjuvant along with formulation innovations that significantly improve controllability, stability, and accessibility. These advances provide key technological support for next-generation vaccine development. In this presentation, Dr. Yin will introduce BDSyn’s breakthroughs in fully synthetic QS-21 adjuvants and high-efficiency formulation platforms, discuss how chemical and materials science approaches overcome limitations associated with natural adjuvant sources, uniformity, and applicability, and outline the platform’s potential in infectious diseases and cancer immunotherapy.